Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Deferred Tax (2016 - 2018)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Deferred Tax over the past 4 years, most recently at $17.5 million for Q2 2018.

  • For Q2 2018, Long-Term Deferred Tax fell 28.87% year-over-year to $17.5 million; the TTM value through May 2018 reached $17.5 million, down 28.87%, while the annual FY2018 figure was $17.5 million, 28.87% down from the prior year.
  • Long-Term Deferred Tax for Q2 2018 was $17.5 million at Lifecore Biomedical, Inc. \De\, down from $24.6 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $32.2 million in Q2 2015 and troughed at $17.5 million in Q2 2018.
  • A 4-year average of $24.2 million and a median of $23.5 million in 2016 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: crashed 30.37% in 2016 and later increased 9.53% in 2017.
  • Year by year, Long-Term Deferred Tax stood at $32.2 million in 2015, then crashed by 30.37% to $22.4 million in 2016, then grew by 9.53% to $24.6 million in 2017, then decreased by 28.87% to $17.5 million in 2018.
  • Business Quant data shows Long-Term Deferred Tax for LFCR at $17.5 million in Q2 2018, $24.6 million in Q2 2017, and $22.4 million in Q2 2016.